ADCT vs TMO · rev $70.8M vs P/E 24, rev $44.56B
ADC Therapeutics SA (ADCT) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
ADCT currently screens at market cap $141.2M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the ADCT and TMO stock pages for the full models.
Not investment advice.